Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$260.88
-0.1%
$220.19
$184.63
$261.64
$461.26B0.38.34 million shs7.10 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$262.52
-0.2%
$233.72
$154.21
$263.10
$633.19B0.248.38 million shs7.95 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$79.76
$53.50
$22.28
$81.40
$31.65B0.948.59 million shs14.01 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.74
$9.23
$6.20
$11.97
$1.60B2.434.17 million shs4.85 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+3.72%+16.04%+24.95%+36.74%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.09%+14.98%+8.06%+68.72%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+18.57%+54.60%+62.11%+163.41%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+9.68%-4.42%+26.49%+44.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$260.88
-0.1%
$220.19
$184.63
$261.64
$461.26B0.38.34 million shs7.10 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$262.52
-0.2%
$233.72
$154.21
$263.10
$633.19B0.248.38 million shs7.95 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$79.76
$53.50
$22.28
$81.40
$31.65B0.948.59 million shs14.01 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.74
$9.23
$6.20
$11.97
$1.60B2.434.17 million shs4.85 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+3.72%+16.04%+24.95%+36.74%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.09%+14.98%+8.06%+68.72%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+18.57%+54.60%+62.11%+163.41%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+9.68%-4.42%+26.49%+44.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$253.81-2.71% Downside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.74
Moderate Buy$256.70-2.22% Downside
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$37.13-53.44% Downside
Novavax, Inc. stock logo
NVAX
Novavax
2.22
Hold$13.0033.47% Upside

Current Analyst Ratings Breakdown

Latest JNJ, MRNA, NVAX, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/26/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Set Price Target$270.00
6/26/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price TargetBuy$266.00 ➝ $270.00
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingMarket Perform
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingOverweight
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetBuy$265.00 ➝ $273.00
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingOverweight$298.00
6/22/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Set Price Target$260.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
DowngradeBuy (B)Buy (B-)
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.54$15.13 per share17.24($1.83) per share-142.56
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B6.71$14.09 per share18.63$33.85 per share7.76
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B16.28N/AN/A$22.14 per share3.60
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.43$3.50 per share2.78($0.79) per share-12.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$2.03128.5116.270.865.79%-576.45%13.39%7/31/2026 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6530.3520.832.5821.83%32.60%13.29%7/15/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)

Latest JNJ, MRNA, NVAX, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.79N/AN/AN/A$16.77 billionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.00N/AN/AN/A$101.75 millionN/A
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.83N/AN/AN/A$25.01 billionN/A
5/6/2026Q1 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/29/2026Q1 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.65%+6.80%340.89%53 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.04%+5.25%61.97%64 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest JNJ, MRNA, NVAX, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.733.19%7/15/20267/15/20268/14/2026
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.33%5/26/20265/26/20266/9/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.80
0.68
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.48
2.45

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.44 million161.81 millionOptionable

Recent News About These Companies

Novavax (NVAX) Stock Moves 1.36%: What You Should Know

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$260.88 -0.19 (-0.07%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$260.14 -0.74 (-0.28%)
As of 07/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$262.52 -0.52 (-0.20%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$262.77 +0.26 (+0.10%)
As of 07/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$79.76 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$80.47 +0.71 (+0.89%)
As of 07/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$9.74 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$9.67 -0.07 (-0.73%)
As of 07/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.